Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder

AUTOR(ES)

Bohle, Andreas

FONTE

International braz j urol

DATA DE PUBLICAÇÃO

2010-08

RESUMO

Documentos Relacionados

• Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993)
• Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder
• Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
• Imaging appearance of granulomatous disease after intravesical Bacille Calmette-Guerin (BCG) treatment of bladder carcinoma
• THE PROPHYLACTIC VALUE OF BACILLUS CALMETTE-GUÉRIN